Drug Profile
Research programme: estrogen receptor peptide - eXegenics
Alternative Names: Estrogen receptor peptide research programme - eXegenicsLatest Information Update: 25 Aug 2003
Price :
$50
*
At a glance
- Originator University of California at Los Angeles
- Developer eXegenics; University of California at Los Angeles
- Class
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 25 Aug 2003 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
- 01 Aug 2003 Suspended - Preclinical for Breast cancer in USA (unspecified route)
- 09 Nov 2001 Cytoclonal Pharmaceutics is now called eXegenics